Drug Profile


Alternative Names: ASP 4130; AV-951; Kil8951; KRN-951; Tivopath

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; Institute Gustave-Roussy; Kyowa Hakko Kirin
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Renal cell carcinoma
  • Phase I Solid tumours
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 27 Feb 2017 TIVO-3 study completes the first safety review by the Safety Monitoring Committee
  • 09 Feb 2017 EUSA Pharma receives Day 180 List of Outstanding Issues from CHMP for tivozanib
  • 28 Nov 2016 EUSA Pharma has submits responses to the EMA Day 120 List of Questions, issued by the CHMP as part of the MAA for tivozanib
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top